Tag: Myostatin inhibitors

The prevalence of sarcopenia, or age-related muscle loss, affects 5% to 13% of individuals aged 60–70 and can rise to 50% in those over 80 [1.9.3]. This article explores the key question: **what drugs improve muscle strength?**

Since 2008, the World Anti-Doping Agency (WADA) has explicitly banned myostatin inhibitors for athletes. This reflects a global concern over their misuse as performance-enhancing drugs, even as the question 'Are myostatin inhibitors legal?' continues to arise for medical and general purposes. Currently, no myostatin inhibitor is approved by the FDA for general human use, though research continues for specific medical conditions.